• Je něco špatně v tomto záznamu ?

Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial

B. Melichar, E. Casado, J. Bridgewater, J. Bennouna, M. Campone, P. Vitek, JP. Delord, J. Cerman, R. Salazar, J. Dvorak, C. Sguotti, P. Urban, K. Viraswami-Appanna, E. Tan, J. Tabernero

. 2011 ; 105 (11) : 1646-1653. [pub] 20111025

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze I, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022152
E-zdroje Online Plný text

NLK Free Medical Journals od 1947 do Před 1 rokem
Freely Accessible Journals od 1947 do Před 1 rokem
PubMed Central od 1947 do Před 1 rokem
Europe PubMed Central od 1947 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1947-01-01
Open Access Digital Library od 1999-01-01
Medline Complete (EBSCOhost) od 1999-01-01 do 2015-11-17
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 22027708
DOI 10.1038/bjc.2011.438
Knihovny.cz E-zdroje

BACKGROUND: New agents that are active in patients with metastatic colorectal cancer are needed. Patupilone (EPO906; epothilone B) is a novel microtubule-stabilising agent. METHODS: Patients with advanced colon cancer who progressed after prior treatment regimens received intravenous patupilone (6.5-10.0 mg m(-2)) once every 3 weeks by a 20-min infusion (20MI), 24-h continuous infusion (CI-1D) or 5-day intermittent 16-h infusion (16HI-5D). Adverse events (AEs), dose-limiting toxicities (DLTs), pharmacokinetics and anti-tumour activity were assessed. RESULTS: Sixty patients were enrolled. The maximum tolerated dose (MTD) was not reached in the 20MI arm (n=31), as no DLTs were observed. Three patients in the CI-1D arm (n=26) experienced 1 DLT each at 7.5, 8.0 and 9.0 mg m(-2), but MTD was not reached. However, the prolonged 16HI-5D arm was terminated at 6.5 mg m(-2) after two of the three patients developed a DLT. Diarrhoea was the most common AE and DLT, with increased severity at the higher doses (9.0 and 10.0 mg m(-2)). Grade 3 or 4 diarrhoea was observed in 11 (35%) of the patients in the 20MI arm, 4 (15%) of the patients in the CI-1D arm and 2 (67%) of the patients in the 16HI-5D arm. Patupilone activity was observed in the 20MI arm with a disease control rate of 58%, including four confirmed partial responses. The disease control rate in CI-1D arm was 39%. CONCLUSION: Patupilone given once every 3 weeks as a 20-min infusion had promising anti-tumour activity and manageable safety profile at doses that demonstrated therapeutic efficacy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022152
003      
CZ-PrNML
005      
20160128095503.0
007      
ta
008      
120806s2011 xxk f 000 0#eng||
009      
AR
024    7_
$a 10.1038/bjc.2011.438 $2 doi
035    __
$a (PubMed)22027708
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853 $u Charles University Medical School and Teaching Hospital, Sokolská 581, Hradec Králové; Department of Oncology, Palacky with grave over University Medical School and Teaching Hospital, Olomouc, Czech Republic
245    10
$a Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial / $c B. Melichar, E. Casado, J. Bridgewater, J. Bennouna, M. Campone, P. Vitek, JP. Delord, J. Cerman, R. Salazar, J. Dvorak, C. Sguotti, P. Urban, K. Viraswami-Appanna, E. Tan, J. Tabernero
520    9_
$a BACKGROUND: New agents that are active in patients with metastatic colorectal cancer are needed. Patupilone (EPO906; epothilone B) is a novel microtubule-stabilising agent. METHODS: Patients with advanced colon cancer who progressed after prior treatment regimens received intravenous patupilone (6.5-10.0 mg m(-2)) once every 3 weeks by a 20-min infusion (20MI), 24-h continuous infusion (CI-1D) or 5-day intermittent 16-h infusion (16HI-5D). Adverse events (AEs), dose-limiting toxicities (DLTs), pharmacokinetics and anti-tumour activity were assessed. RESULTS: Sixty patients were enrolled. The maximum tolerated dose (MTD) was not reached in the 20MI arm (n=31), as no DLTs were observed. Three patients in the CI-1D arm (n=26) experienced 1 DLT each at 7.5, 8.0 and 9.0 mg m(-2), but MTD was not reached. However, the prolonged 16HI-5D arm was terminated at 6.5 mg m(-2) after two of the three patients developed a DLT. Diarrhoea was the most common AE and DLT, with increased severity at the higher doses (9.0 and 10.0 mg m(-2)). Grade 3 or 4 diarrhoea was observed in 11 (35%) of the patients in the 20MI arm, 4 (15%) of the patients in the CI-1D arm and 2 (67%) of the patients in the 16HI-5D arm. Patupilone activity was observed in the 20MI arm with a disease control rate of 58%, including four confirmed partial responses. The disease control rate in CI-1D arm was 39%. CONCLUSION: Patupilone given once every 3 weeks as a 20-min infusion had promising anti-tumour activity and manageable safety profile at doses that demonstrated therapeutic efficacy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antitumorózní látky $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000970
650    _2
$a nádory tračníku $x farmakoterapie $x metabolismus $x patologie $7 D003110
650    _2
$a progrese nemoci $7 D018450
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a epothilony $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D034261
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $x metody $7 D007262
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a maximální tolerovaná dávka $7 D020714
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Casado, E. $u Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Pl. Vall d'Hebron 119-129, 08035 Barcelona, Spain
700    1_
$a Bridgewater, J. $u University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK
700    1_
$a Bennouna, J. $u Centre de Recherche en Cancérologie, UMR-INSERM 892, Institut de Cancérologie de l'Ouest/René Gauducheau, Bd. Jacques Monod, 44805 Saint-Herblain, Nantes, France
700    1_
$a Campone, M. $u Centre de Recherche en Cancérologie, UMR-INSERM 892, Institut de Cancérologie de l'Ouest/René Gauducheau, Bd. Jacques Monod, 44805 Saint-Herblain, Nantes, France
700    1_
$a Vitek, P. $u Institute of Radiation Oncology, Charles University First Medical School, Praha, Czech Republic
700    1_
$a Delord, J-P. $u Institut Claudius Regaud, 20-24 rue de Pont Saint Pierre, 31052 Toulouse, France
700    1_
$a Cerman, Jaroslav $7 xx0127748 $u Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic
700    1_
$a Salazar, R. $u Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Pl. Vall d'Hebron 119-129, 08035 Barcelona, Spain
700    1_
$a Dvorak, J. $u Charles University Medical School and Teaching Hospital, Hradec Králové, Czech Republic
700    1_
$a Sguotti, C. $u Novartis Pharma AG, Oncology Clinical Development, 4202 Basel, Switzerland
700    1_
$a Urban, P. $u Novartis Pharma AG, Oncology Clinical Development, 4202 Basel, Switzerland
700    1_
$a Viraswami-Appanna, K. $u Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover 07936-1080, NJ, USA
700    1_
$a Tan, E. $u Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover 07936-1080, NJ, USA
700    1_
$a Tabernero, J. $u Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Pl. Vall d'Hebron 119-129, 08035 Barcelona, Spain
773    0_
$w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 105, č. 11 (2011), s. 1646-1653
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22027708 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20160128095629 $b ABA008
999    __
$a ok $b bmc $g 944065 $s 779449
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 105 $c 11 $d 1646-1653 $e 20111025 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
LZP    __
$b NLK111 $a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Možnosti archivace